Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Valion Bio, Inc.
organization11 mentionslast seen Nov 9, 2026
Biopharmaceutical company developing biologics for cytoprotection and immune modulation.
Relationships 19
- Valion Bio, Inc.employsDean Zikria99% confidence10 sources
- Valion Bio, Inc.developsEntolimod99% confidence8 sources
- Valion Bio, Inc.developsEntolasta99% confidence7 sources
- Valion Bio, Inc.ownsVelocity Bioworks99% confidence7 sources
- Valion Bio, Inc.depends onStatera Biopharma99% confidence3 sources
- Valion Bio, Inc.employsLisa Wolf99% confidence2 sources
- Valion Bio, Inc.partners withShear Kershman Laboratories99% confidence2 sources
- 3i, LPinvests inValion Bio, Inc.99% confidence2 sources
- Valion Bio, Inc.employsThomas H. Jensen98% confidence1 source
- Valion Bio, Inc.employsMelinda Lackey97% confidence1 source
- 3i, LPinvests inValion Bio, Inc.95% confidence1 source
- 3i, LPinvests inValion Bio, Inc.95% confidence1 source
- Velocity BioworkssuppliesValion Bio, Inc.94% confidence1 source
- Valion Bio, Inc.developsoral mucosal Entolimod formulation94% confidence1 source
- Valion Bio, Inc.funded bySeries B funding round93% confidence1 source
- Valion Bio, Inc.funded bySeries C funding round93% confidence1 source
- Valion Bio, Inc.partners withSheba Medical Center92% confidence1 source
- Armed Forces Radiobiology Research Institutepartners withValion Bio, Inc.90% confidence1 source
- Valion Bio, Inc.commercializesEntolimod85% confidence1 source
Relationship
Valion Bio, Inc.developsEntolimod
99% confidence8 supporting mentions
Either name opens that entity’s relationships.
Sources 8
- filingSEC EDGARNov 2, 2026Valion Bio, Inc. 8-K: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion Bio, Inc. (NASDAQ: VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics
- filingSEC EDGAROct 29, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion Bio, Inc. (NASDAQ: VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced final data from a National Institute of Allergy and Infectious Diseases ("NIAID")/Radiation and Nuclear Countermeasures Program ("RNCP")-funded safety study of its lead biologic drug candidate, Entolimod
- filingSEC EDGAROct 26, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
its lead biologic drug candidate, Entolimod
- filingSEC EDGAROct 22, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod, Valion's lead biologic drug candidate for Acute Radiation Syndrome
- filingSEC EDGAROct 15, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company's lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome
- filingSEC EDGAROct 14, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today highlighted the capabilities of its wholly owned contract development and manufacturing organization ("CDMO"), Velocity Bioworks. Velocity Bioworks ("Velocity") is part of Valion's own domestic biologics supply chain, supporting the Company's development strategy for its lead candidate, Entolimod
- filingSEC EDGAROct 6, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod is an investigational Toll-like receptor 5 (TLR5) agonist being developed
- filingSEC EDGAROct 1, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion holds an exclusive worldwide license from Statera Biopharma to develop and commercialize Entolimod